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INTRODUCTION:  Hemangiopericytoma  (HPC)/solitary  ﬁbrous  tumor  (SFT)  is  a  very  uncommon  tumor  of
uncertain  malignant  behavior.  In  1942,  Stout  and  Murray  ﬁrst characterized  these  neoplasms  as  “vascular
tumors  arising  from  Zimmerman’s  pericytes”  and  till  now  hemangiopericytomas  and  solitary  ﬁbrous
tumors  of  the soft  tissues  are  regarded  as  features  of the  same  entity  in  the soft  tissue  fascicle.
PRESENTATION OF CASE:  We  present  a  case  of hemangiopericytoma/solitary  ﬁbrous  tumor  of  the  pectoralis
major  muscle  in  a 33-year-old  female.  She  ﬁrst  noticed  a painless  mass  in her  right  breast.  Ultrasound  of
the  breast  revealed  a large  heterogeneously  hypoechoic  lesion  within  the pectoralis  major  muscle.  Fine
needle  aspiration  of  the  tumor  did  not  produce  any  meaningful  result.  The  lesion  was  completely  removed
by  surgical  resection.  Histologically,  the  tumor  had  staghorn-like  vasculature  and  immunohistochemistry
for  CD34  was  positive,  whereas  desmin,  smooth-muscle  actin,  S-100  protein,  cytokeratins  (AE1/AE3)
and  epithelial  membrane  antigen  (EMA)  were  all negative.  A diagnosis  of  hemangiopericytoma/solitary
ﬁbrous  tumor  was  rendered.
DISCUSSION: Tumors  comprising  the  HPC/SFT  spectrum  represent  a small  subset  of  soft  tissue  sarcomas
and  are  found  virtually  at any  site  in  the  body.  Wide surgical  resection  can  achieve  favorable  long-term
survival.
CONCLUSION:  Due  to the rarity  and  unpredictable  biological  potential  of  these  tumors,  long-term  follow-
up  is  mandatory  even  after radical  resection,  because  recurrence  or development  of  metastasis  may  be
delayed  many  years.
gical © 2013 Sur
. Introduction
A  wide range of soft tissue neoplasms has to be consid-
red in the differential diagnosis of pectoral area nodules. In
oft tissues, the histological growth pattern cannot securely
stablish a correct diagnosis, as many tumors such as myoﬁbrob-
astoma, schwannoma, synovial sarcoma, dermato ﬁbrosarcoma
rotuberans, spindle cell carcinoma, leiomyosarcoma, low-grade
bromyxoid sarcoma, malignant peripheral nerve sheath tumor
nd liposarcoma share similar clinicopathological features. There-
ore, it is essential an experienced soft tissue pathologist should
valuate the specimens.1
Hemangiopericytoma represents less than 2% of these soft tis-
ue tumors and was once regarded as a vascular, pericyte-derived
umor, but recently has been categorized as a ﬁbroblastic neoplasm
imilar to solitary ﬁbrous tumor. Both of them probably belong to a
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spectrum of a single pathologic entity, a concept supported by their
overlapping histological and clinical features.1,2
2. Presentation of case
A 33-year-old woman  became aware of a non-tender lump in
the outer upper quadrant of her right breast. She had ﬁrst noticed
the mass 1 month ago. Her family history was  unremarkable, as was
her medical history. On physical examination, the patient had a pal-
pable, soft tumor, approximately 4 cm in diameter and was located
on the upper outer aspect of the right axillary tail near the chest
wall. It was a well-deﬁned, mobile mass, not adherent to either
the skin or chest wall. No axillary lymph nodes were found and all
laboratory studies were within normal limits.
Targeted breast ultrasonography demonstrated a large hetero-
geneous and hypoechoic lesion, contiguous to the pectoralis major
muscle with its largest dimension approximately 3.5 cm (Fig. 1a).
Open access under CC BY-NC-ND license.Profound color ﬂow signals were evident in both central and
peripheral regions of the mass (Fig. 1b). Fine-needle aspiration was
performed, but did not retrieve any meaningful tissue. The patient
eventually underwent an excisional biopsy and frozen section
NC-ND license.
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Fig. 2. (a) Histologic section showing spindle and ovoid cells, with moderately
irregular, without atypia (Hematoxylin and Eosin stain; original magniﬁcation ×40).
(b) Higher magniﬁcation microphotograph demonstrating the presence of thin
branching vessels within the mass (Hematoxylin and Eosin stain; original magniﬁ-
cation ×100).ig. 1. (a) Targeted breast ultrasosongraphy revealing a heterogeneous hypoechoic
esion conﬁned to the pectoralis major muscle. (b) Increased intratumoral and per-
tumoral blood ﬂow on Doppler sonography.
nalysis conﬁrmed the presence of a mesenchymal tumor of
nknown biological potential.
Histology revealed a 5 cm ×3 cm whitish lesion, with a smooth
urface, surrounded by a thin, ﬁbrous capsule. The mass was con-
ned to the superﬁcial layer of the pectoralis major muscle, but
id not inﬁltrate the subcutaneous tissue or the pectoral fascia. At
igher magniﬁcation, there were bundles of spindle and ovoid cells,
ith moderately irregular nuclei and low mitotic activity (2–3 per
0 high-power ﬁelds), resembling a benign mesenchymal tumor
Fig. 2a). Numerous thin-walled and branching vessels within the
ytoplasma were present (Fig. 2b). Foci of chronic inﬂammation,
yxoid change, and mast cells were also observed, but no necrosis
r cellular atypia was evident.
The immunohistochemical proﬁle included intense membrane
ositivity for CD34 (Fig. 3), but the lesion did not stain for desmin,
mooth-muscle actin (SMA), and S-100 protein (Fig. 4a–c). It
as also uniformly negative for cytokeratins (AE1/AE3), epithelial
embrane antigen (EMA), whereas the proliferative index was low
Ki-67 < 4%). These diverse histological and immunohistochemical
ndings therefore established the diagnosis of hemangiopericy-
oma/solitary ﬁbrous tumor.
Twenty months later she remains well, without tumor recur-
ence.. Discussion
HPC/SFT is an exceedingly obscure tumor of uncertain malig-
ant potential and controversial categorization. Approximately 300Fig. 3. Diffuse, strong immunohistochemical staining for CD34 of the spindle-cell
component.
cases of HPC have been published since Stout and Murray described
HPC as “vascular tumor arising from Zimmerman’s pericytes” in
1942. After further characterization, the WHO  reclassiﬁed HPC
as a ﬁbroblastic/myoﬁbroblastic neoplasm. On the other hand,
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gig. 4. Negative expression of the neoplastic cells by (a) desmin, (b) smooth muscle
ctin, and (c) S-100 protein (Avidin Biotin ×200).
FT was ﬁrst reported by Wagner in 1870, as a similar lesion
eveloping from the small oval or spindle-shaped pericytes lining
apillaries.1,3,4
HPC/SFTs have been described at almost every anatomic loca-
ion. Most case series showed almost equal distribution for male
nd female patients, with ages ranging from the third to the
ighth or ninth decade with a maximum incidence in the ﬁfth to
ixth decade.4,5 The differential diagnosis is the most demanding
nd rather confusing issue of a HPC/SFT lesion. Morphologically,
PC/SFT is generally characterized by spindle cell proliferation
howing a pattern-less architecture and staghorn vasculature, but
he ﬁnal diagnosis is conﬁrmed by immunohistochemistry using
 monoclonal antibody against the human hematopoietic pro-
enitor cell antigen stain (CD34), as in our case report. CD34PEN  ACCESS
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immunoreactivity has been reportedly revealed to be strongly and
diffusely expressed in many cases of HPC/SFTs, but it is not spe-
ciﬁc for SFT or HPC alone.4 Some studies suggest that additional
immunoreactivities of bcl2 and CD99 are also diffusely positive
in most SFTs. This feature can sometimes differentiate SFTs from
HPC, because this spectrum of tumors shares similar histologi-
cal pattern and CD34 reactivity. However, bcl2 and CD99 were
not available in our immunochemistry panel. Vimentin, keratin,
smooth muscle antigen (SMA), EMA, desmin, CD117 and S-100 pro-
tein are sometimes useful for differential diagnosis of HPC/SFT from
tumors with muscle, epithelial or neural origin. Several researchers
have proposed that these two neoplasms represent the same
entity, especially in lipomatous hemangiopericytoma and the fat-
containing variant of SFT. On the other hand, other authors stated
that the presence of spindle cell cytological features, various growth
patterns with overlapping hypocellular and hypercellular areas and
abundant collagenization is indicative of SFT diagnosis, whereas
the existence of round or oval nuclei and diffuse stag-horn vas-
cular pattern favors a HPC diagnosis.6,7 In our case report, HPC/SFT
was regarded as the ﬁnal pathology result, as abundant spindle and
ovoid cellularity and widespread stag-horn vascularity were both
equally present.
Nuclear atypia, areas of high cellularity or necrosis, increased
mitotic index (>4 mitoses per 10 high-power ﬁelds), large tumor
size (>50 mm)  and inﬁltrative margins are regarded as criteria of
HPC/SFT malignancy and positively correlated with local recur-
rence and metastatic disease. Some studies demonstrated a very
low rate of recurrence and distant metastasis, whereas other inves-
tigators indicated a relatively increased relapse rate with extended
follow-up periods. Therefore, complete resection at an early stage
should be the main goal of surgical treatment and follow-up should
be maintained for more than 10 years.1,3 Vallat-Decouvelaere et al.
in their study found local recurrence in 4.3% and metastasis in
6.7%, while Gold et al. reported rates of 5.4% and 5.3%, respec-
tively. Tumor relapse occurred after up to 168 months, but most
local recurrences or metastases were diagnosed within the ﬁrst
2 years after surgery. Sites of distant metastasis were lung, liver,
bones, mesentery, omentum, mediastinum and retroperitoneum
with preference for lung and liver.8,9
Nowadays, evolving therapies inhibiting speciﬁc angiogenic
pathways show promising activities in HPC/SFT. The rich vascular
features of HPC/SFT have been long recognized, but the effective
value of the vascular endothelial growth factor (VEGF) and its
receptor (VEGFR) in hemangiopericytoma/solitary ﬁbrous tumor
(HPC/SFT) still remains indistinct. Several phase II trials have inves-
tigated the efﬁcacy of bevacizumab, an anti-VEGF antibody, and
VEGFR tyrosine kinase inhibitors (TKIs), such as sunitinib, sorafenib
and pazopanib, whereas combination therapy with temozolomide
and bevacizumab has recently emerged as an encouraging ther-
apeutic regime for HPC/SFT. These targeted agents do not clearly
beneﬁt the majority of patients, indicating that biological mecha-
nisms underlying the activity of these agents in HPC/SFT are still
poorly understood.3
Complete surgical resection is commonly accepted as the cur-
rent cornerstone of curative intent. Due to improved techniques
in reconstructive surgery, large lesions or even recurrent tumors
can usually be entirely resected. For HPC/SFT displaying malignant
behavior or positive surgical margins after excision, adjuvant radio-
therapy is recommended, when feasible. On the other hand, there is
no strong evidence supporting the use of adjuvant chemotherapy.
Long-term follow is mandatory, because local or distant relapse can
occur after resection of an HPC/SFT which appears histologically
benign.1,10Conﬂict of interest
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